Monday, August 29, 2016

WB drops coverage of OncoGenex

WB drops coverage of OncoGenex

August 16, 2016 by · Leave a Comment 

Tweet William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday. “We note that AFFINITY is the key study of the lead asset, custirsen, as a chemotherapy companion in the second-line chemo setting in metastatic castration […]

Mackie starts Profound Medical at speculative buy

Mackie starts Profound Medical at speculative buy

August 10, 2016 by · Leave a Comment 

Tweet Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday. “Relative to all approved prostate cancer treatments, we believe TULSA-PRO can clearly be differentiated with its clean safety profile, as well as decent efficacy,” […]

Maxim ups Sophiris price target to $6

Maxim ups Sophiris price target to $6

August 10, 2016 by · Leave a Comment 

Tweet Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday. As the datasets for topsalysin continue to develop, the marketplace appears to be recognizing the potential in both oncology and benign prostatic hyperplasia,” writes […]

Essa Pharma names Peter Virsik as EVP, COO

Essa Pharma names Peter Virsik as EVP, COO

August 2, 2016 by · Leave a Comment 

Tweet Essa Pharma (NASDAQ:EPIX; TSX:EPI) has appointed Peter Virsik as executive vice-president and chief operating officer. Mr. Virsik will be responsible for leading Essa’s overall business development and corporate strategy as the company further advances a clinical development plan for its novel prostate cancer therapeutic, EPI-506. Mr. Virsik is a seasoned biopharmaceutical executive with over […]

BioLight’s CellDetect posts positive results in prostate cancer

BioLight’s CellDetect posts positive results in prostate cancer

July 26, 2016 by · Leave a Comment 

Tweet BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage. The CellDetect technology is being developed by Micromedic Technologies […]

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Profound Medical, Royal Philips sell TULSA-PRO in Germany

Profound Medical, Royal Philips sell TULSA-PRO in Germany

June 21, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative, minimally-invasive technique used to treat clinically organ-confined prostate cancer. The unique technology combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop […]

Profound Medical, Royal Philips sell TULSA-PRO in UK

Profound Medical, Royal Philips sell TULSA-PRO in UK

June 20, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system in the UK to University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH). This marks the first sale under the company’s recent collaboration with Philips, following Profound’s receipt of CE Mark approval in April 2016. TULSA-PRO is a […]

ESSA Pharma takes unique approach to prostate cancer

ESSA Pharma takes unique approach to prostate cancer

June 7, 2016 by · Leave a Comment 

Tweet A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the BC Cancer Agency and the University of British Columbia spent more than a decade conducting the basic biology research, identifying […]

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

Next Page »

Email Newsletters with Constant Contact
Google+